Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma.
Herling
Marco
M
Rassidakis
George Z
GZ
Vassilakopoulos
Theodoros P
TP
Medeiros
L Jeffrey
LJ
Sarris
Andreas H
AH
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D005260:Female; D015967:Gene Expression Regulation, Viral; D006689:Hodgkin Disease / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D014763:Viral Matrix Proteins / Q000096:biosynthesis*
C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins